Evidence map›Paper›PMID 15489887›Full record

ArticleOncogene2004

Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase.

Charles E Ducker, Erin M Stettler, Kevin J French, John J Upson, Charles D Smith

Abstract read
In one paragraph

Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Cancer: From Wild-Type to Mutant Huntingtin.Journal of Huntington's disease · 2018
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Charles E DuckerDepartment of Pharmacology, H078, Penn State College of Medicine, 500 University Drive Hershey, PA 17033, USA.
Erin M Stettler
Kevin J French
John J Upson
Charles D Smith
Pennsylvania State University · US

Funding

ACYLTRANSFERASE INHIBITORS AS ANTI RAS AGENTSR01CA075248 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SMITH, CHARLES D. · 1997 to 2009
$2.2M
NCI NIH HHS R01 CA075248NCI NIH HHS R01 CA75248
6 · The paper itself

Abstract

Protein palmitoyltransferases (PATs) represent an exciting new target for anticancer drug design due to their pivotal roles in the subcellular localization of a number of oncogenes. We show that the Huntingtin interacting protein 14 (HIP14) is a PAT with a preference for the farnesyl-dependent palmitoylation motif found in H- and N-RAS. Characterization of HIP14 in mouse cells has revealed that it has the ability to induce colony formation in cell culture, anchorage-independent growth, and tumors in mice. Activity of the enzyme and its ability to transform cells is dependent on critical residues in the active site of the enzyme.

Indexed as

AcyltransferasesAdaptor Proteins, Signal TransducingAnimalsBase SequenceCarrier ProteinsCell Transformation, NeoplasticDNA PrimersFemaleHumansMiceMice, Inbred NODMice, SCIDNerve Tissue ProteinsNIH 3T3 CellsAcyltransferasesAdaptor Proteins, Signal TransducingCarrier ProteinsDNA PrimersNerve Tissue ProteinsZDHHC17 protein, human

Identifiers

PMID15489887
PMCPMC2908390
OpenAlexW1972678327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.